本文選題：左西孟旦 + 硫酸特布他林　； 參考：《中國臨床藥理學雜志》2017年16期

【摘要】：目的觀察左西孟旦聯(lián)合硫酸特布他林治療慢性阻塞性肺疾病伴心功能不全的臨床療效及安全性。方法將88例慢性阻塞性肺疾病伴心功能不全患者隨機分為對照組44例與試驗組44例,2組均給予常規(guī)治療及對癥治療。對照組給予吸入用布地奈德混懸液1 mg+硫酸特布他林霧化液5 mg于射流霧化器內(nèi),氧氣驅(qū)動霧化吸入,每日2次,呋塞米20~40 mg,靜脈推注2~3 h。試驗組在對照組的基礎上給予左西孟旦0.1μg·kg~(-1)·min~(-1)靜脈輸注,持續(xù)給藥24 h。2組患者均持續(xù)用藥7 d。比較2組患者的臨床療效、肌鈣蛋白T、心肌酶譜、心肺功能及藥物不良反應發(fā)生情況。結(jié)果治療后,試驗組總有效率為88.64%(39/44例),對照組為70.45%(31/44例,P0.05)。治療后,對照組和試驗組肌鈣蛋白T分別為(0.48±0.06),(0.18±0.03)μg·L~(-1);肌酸激酶分別為(189.29±21.30),(130.27±16.11)U·L~(-1);肌酸激酶同工酶分別為(11.34±1.71),(8.87±1.09)U·L~(-1);乳酸脫氫酶分別為(159.29±17.11),(138.70±14.51)U·L~(-1);左心室舒張末期內(nèi)徑分別為(50.29±5.79),(47.01±5.01)mm;第1秒用力呼氣量分別為(1.35±0.19),(1.70±0.23)L;第1秒用力呼氣量/用力肺活量(FEV1/FVC)分別為(60.93±7.09)%,(76.94±8.58)%;左心室射血分數(shù)分別為(42.39±4.58)%,(51.29±5.71)%;6 min內(nèi)的最大步行距離分別為(260.39±29.21),(324.29±35.16)m,差異均有統(tǒng)計學意義(均P0.05)。試驗組的藥物不良反應有心悸、頭痛、眩暈,藥物不良反應發(fā)生率為6.82%(3/44例);對照組的藥物不良反應有體位性低血壓、低鈉血癥、心律失常、口渴,藥物不良反應發(fā)生率為11.36%(5/44例),差異無統(tǒng)計學意義(P0.05)。結(jié)論左西孟旦聯(lián)合硫酸特布他林治療慢性阻塞性肺疾病伴心功能不全的臨床療效較高,安全性高。
[Abstract]:Objective to observe the efficacy and safety of levosimendan combined with terbutaline sulfate in the treatment of chronic obstructive pulmonary disease with cardiac insufficiency. Methods 88 patients with chronic obstructive pulmonary disease complicated with cardiac insufficiency were randomly divided into control group (n = 44) and experimental group (n = 44). The control group was treated with budesonide suspension (1 mg) and terbutaline sulfate (5 mg) in the jet atomizer. Oxygen driven atomization was administered twice a day, furosemide 2040 mg, intravenous injection for 23 h. On the basis of the control group, the patients in the trial group were given levsimendan 0.1 渭 g / kg, 1 渭 g / min / min, iv infusion, and the patients in the 24 h / 2 group were treated continuously for 7 days. The clinical efficacy, cardiac troponin T, myocardial enzyme spectrum, cardiopulmonary function and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rate of the trial group was 88.64 / 39 / 44 cases, and that of the control group was 70.45% / 44 cases (P 0.05). After treatment, 瀵圭収緇勫拰璇曢獙緇勮倢閽欒泲鐧絋鍒嗗埆涓，

本文編號：1911273